MONECO Advisors LLC Purchases 320 Shares of Merck & Co., Inc. (NYSE:MRK)

MONECO Advisors LLC grew its position in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 5.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,533 shares of the company’s stock after buying an additional 320 shares during the quarter. MONECO Advisors LLC’s holdings in Merck & Co., Inc. were worth $536,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of MRK. Norges Bank bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $1,823,028,000. BlackRock Inc. lifted its holdings in shares of Merck & Co., Inc. by 5.5% during the 4th quarter. BlackRock Inc. now owns 198,224,263 shares of the company’s stock valued at $15,191,909,000 after buying an additional 10,326,974 shares during the period. Geode Capital Management LLC increased its stake in shares of Merck & Co., Inc. by 12.7% in the 4th quarter. Geode Capital Management LLC now owns 48,153,283 shares of the company’s stock worth $3,682,009,000 after purchasing an additional 5,409,154 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Merck & Co., Inc. by 13.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 28,981,674 shares of the company’s stock worth $2,221,156,000 after purchasing an additional 3,484,786 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Merck & Co., Inc. by 2.7% in the 4th quarter. State Street Corp now owns 118,668,673 shares of the company’s stock worth $9,174,491,000 after purchasing an additional 3,132,078 shares in the last quarter. 72.88% of the stock is owned by institutional investors.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock traded up $0.30 during trading on Friday, reaching $87.12. 343,588 shares of the stock traded hands, compared to its average volume of 8,495,317. The company has a market capitalization of $220.31 billion, a price-to-earnings ratio of 13.30, a P/E/G ratio of 1.18 and a beta of 0.32. The business has a fifty day simple moving average of $90.38 and a two-hundred day simple moving average of $85.34. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.40 and a quick ratio of 1.14. Merck & Co., Inc. has a 52-week low of $70.89 and a 52-week high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.69 by $0.18. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 50.02%. The firm had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. During the same quarter last year, the firm earned $1.31 EPS. The firm’s revenue for the quarter was up 28.0% compared to the same quarter last year. Sell-side analysts expect that Merck & Co., Inc. will post 7.31 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.17%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s payout ratio is 42.27%.

Wall Street Analyst Weigh In

MRK has been the subject of several analyst reports. SVB Leerink restated an “outperform” rating and issued a $102.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, June 6th. Cowen upped their price objective on Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a research note on Monday, June 27th. Barclays upped their price objective on Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. Morgan Stanley upped their price objective on Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a research note on Friday, July 29th. Finally, Cowen increased their price target on Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a research note on Monday, June 27th. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $97.44.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.